A randomized, open-label, national multicenter, phase III trial studying maintenance treatment with lenalidomide and dexamethasone versus lenalidomide, dexamethasone and MLN9708 after autologous hematopoietic stem cell transplant in patients with newly-diagnosed, symptomatic multiple myeloma.
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2018
Price : $35 *
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 28 Nov 2017 Status changed from recruiting to completed.
- 01 Aug 2014 New trial record